Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.032 | 0.6429 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0431 | 1 | 1 |
Toxoplasma gondii | phosphotransferase enzyme family protein | 0.0174 | 0.173 | 0.5 |
Echinococcus multilocularis | small conductance calcium activated potassium | 0.032 | 0.6429 | 1 |
Schistosoma mansoni | calcium-activated potassium channel | 0.032 | 0.6429 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.032 | 0.6429 | 0.6429 |
Onchocerca volvulus | 0.0431 | 1 | 0.5 | |
Loa Loa (eye worm) | choline/ethanolamine kinase | 0.0174 | 0.173 | 0.173 |
Loa Loa (eye worm) | hypothetical protein | 0.0133 | 0.0439 | 0.0439 |
Plasmodium falciparum | choline kinase | 0.0174 | 0.173 | 0.5 |
Plasmodium vivax | choline kinase, putative | 0.0174 | 0.173 | 0.5 |
Echinococcus granulosus | small conductance calcium activated potassium | 0.032 | 0.6429 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED 50 (functional) | = 0.08 uM | In Vitro evaluation of the compound for the antiproliferative activity by observing the growth inhibition of L1210 lymphoid leukemia cells in culture at 72 hour | ChEMBL. | 7452687 |
ILS (functional) | = 46 % | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 100 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers | ChEMBL. | 7452687 |
ILS (functional) | = 59 % | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 9.2 and 13.2 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers | ChEMBL. | 7452687 |
ILS (functional) | = 77 % | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 18.7 and 26.6 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers | ChEMBL. | 7452687 |
ILS (functional) | = 90 % | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 25 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers | ChEMBL. | 7452687 |
ILS (functional) | = 141 % | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 50 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers | ChEMBL. | 7452687 |
ILS (functional) | = 200 % | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 75 mg/kg/day x 5 was determined as percentage increase in the life span as compared with control tumor bearers | ChEMBL. | 7452687 |
Survival time (functional) | = 10 day | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 100 mg/kg/day x 5 was determined as Survival time in days; Range is 10-16 days | ChEMBL. | 7452687 |
Survival time (functional) | = 12 day | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 18.7 and 26.6 mg/kg/day x 5 was determined as Survival time in days; Range is 12-22 days | ChEMBL. | 7452687 |
Survival time (functional) | = 13 day | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 9.2 and 13.2 mg/kg/day x 5 was determined as Survival time in days; Range is 13-24 days | ChEMBL. | 7452687 |
Survival time (functional) | = 14 day | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 25 mg/kg/day x 5 was determined as Survival time in days; Range is 14-27 days | ChEMBL. | 7452687 |
Survival time (functional) | = 14 day | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 50 mg/kg/day x 5 was determined as Survival time in days; Range is 14-23 days | ChEMBL. | 7452687 |
Survival time (functional) | = 18 day | Antitumor activity in the mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 75 mg/kg/day x 5 was determined as Survival time in days; Range is 18-37 days | ChEMBL. | 7452687 |
Weight change (functional) | = -4.76 g mouse-1 | Antitumor activity in mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 5 mg/kg/day x 9.2 and 13.2 was determined as weight change (g/mouse) on 8th day | ChEMBL. | 7452687 |
Weight change (functional) | = -3.82 g mouse-1 | Antitumor activity in mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 100 mg/kg/day x 5 was determined as weight change (g/mouse) on 8th day | ChEMBL. | 7452687 |
Weight change (functional) | = -2.5 g mouse-1 | Antitumor activity in mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 50 mg/kg/day x 5 was determined as weight change (g/mouse) on 8th day | ChEMBL. | 7452687 |
Weight change (functional) | = -1.36 g mouse-1 | Antitumor activity in mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 18.7 and 26.6 mg/kg/day x 5 was determined as weight change (g/mouse) on 8th day | ChEMBL. | 7452687 |
Weight change (functional) | = 0.46 g mouse-1 | Antitumor activity in mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 75 mg/kg/day x 5 was determined as weight change (g/mouse) on 8th day | ChEMBL. | 7452687 |
Weight change (functional) | = 1.55 g mouse-1 | Antitumor activity in mice with intraperitoneal implanted L1210 lymphoid leukemia at the dose 25 mg/kg/day x 5 was determined as weight change (g/mouse) on 8th day | ChEMBL. | 7452687 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.